Biologic and Checkpoint Inhibitor‐Induced Liver Injury: A Systematic Literature Review

Parth Shah, Vinay Sundaram, Einar Björnsson – 2 January 2020 – Biologics are among the most commonly prescribed medications for several chronic inflammatory diseases. Tumor necrosis factor alpha inhibitors, more so than other agents, have been observed to cause drug‐induced liver injury. Additionally, because the approval and popularity of checkpoint inhibitors have grown, similar patterns of liver injury have been documented, with a majority of cases describing immune‐mediated hepatitis.

Novel Liquid Biopsy Test Based on a Sensitive Methylated SEPT9 Assay for Diagnosing Hepatocellular Carcinoma

Yurika Kotoh, Yutaka Suehiro, Issei Saeki, Tomomi Hoshida, Masaki Maeda, Takuya Iwamoto, Toshihiko Matsumoto, Isao Hidaka, Tsuyoshi Ishikawa, Taro Takami, Shingo Higaki, Ikuei Fujii, Chieko Suzuki, Yoshitaro Shindo, Yukio Tokumitsu, Hiroaki Nagano, Isao Sakaida, Takahiro Yamasaki – 2 January 2020 – Liquid biopsies are not used in practice for hepatocellular carcinoma (HCC). Epi proColon is the first commercial blood‐based test for colorectal cancer screening based on methylated DNA testing of the septin 9 gene (SEPT9).

Service Requirements of Liver Transplant Anesthesia Teams: Society for the Advancement of Transplant Anesthesia Recommendations

Adrian Hendrickse, Cara Crouch, Tetsuro Sakai, William D. Stoll, Monica McNulty, Evan Pivalizza, Srikanth Sridhar, Geraldine Diaz, Patricia Sheiner, Moises I. Nevah Rubin, Ali Al‐Khafaji, James Pomposelli, M. Susan Mandell – 28 December 2019 – There are disparities in liver transplant anesthesia team (LTAT) care across the United States. However, no policies address essential resources for liver transplant anesthesia services similar to other specialists. In response, the Society for the Advancement of Transplant Anesthesia appointed a task force to develop national recommendations.

Subscribe to